Applied Molecular Transport (AMTI) Reports First Patient Dosed in Phase 1a Trial of Oral AMT-126; Expands Clinical Pipeline

Go back to Applied Molecular Transport (AMTI) Reports First Patient Dosed in Phase 1a Trial of Oral AMT-126; Expands Clinical Pipeline

Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126

March 1, 2021 8:00 AM EST

Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects

IL-22 deficiency implicated in broad range of gastrointestinal-focused and peripheral diseases ranging from ulcerative colitis to multiple rheumatologic disorders

Complete oral AMT-126 Phase 1a/b data in healthy volunteers and patients anticipated in 2022

Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program beginning in the second half of 2021

SOUTH SAN... More